Oncotarget

Full Text- http://bit.ly/2DnHaPQ

We, the scientists, should change the situation and change the policies of Indexes such as Clarivate's Web of Science, and Medline, and make indexes work for us. Otherwise, why should all of these organizations exist?

Facebook - bit.ly/2xznxjV

Twitter - bit.ly/2xzWvsu

LinkedIn - bit.ly/2xzJ6kc

Pintrest - bit.ly/2xzX8SS

Reddit - bit.ly/2hoxI0N

www.Oncotarget.com

Symmetry and symmetry breaking in cancer: a foundational approach to the cancer problem

https://tinyurl.com/yab9jbxb

Symmetry and symmetry breaking concepts from physics and biology are applied to the problem of cancer. Three categories of symmetry breaking in cancer are examined: combinatorial, geometric, and functional. Within these categories, symmetry breaking is examined for relevant cancer features, including epithelial-mesenchymal transition (EMT); tumor heterogeneity; tensegrity; fractal geometric and information structure; functional interaction networks; and network stabilizability and attack tolerance. The new cancer symmetry concepts are relevant to homeostasis loss in cancer and to its origin, spread, treatment and resistance. Symmetry and symmetry breaking could provide a new way of thinking and a pathway to a solution of the cancer problem.

Facebook - bit.ly/2xznxjV

Twitter - bit.ly/2xzWvsu

LinkedIn - bit.ly/2xzJ6kc

Pintrest - bit.ly/2xzX8SS

Reddit - bit.ly/2hoxI0N

www.Oncotarget.com

Effective control of acute myeloid leukaemia and acute lymphoblastic leukaemia progression by telomerase specific adoptive T-cell therapy

Full Text- https://tinyurl.com/yb3gjwqs

Telomerase (TERT) is a ribonucleoprotein enzyme that preserves the molecular organization at the ends of eukaryotic chromosomes. Since TERT deregulation is a common step in leukaemia, treatments targeting telomerase might be useful for the therapy of hematologic malignancies. Despite a large spectrum of potential drugs, their bench-to-bedside translation is quite limited, with only a therapeutic vaccine in the clinic and a telomerase inhibitor at late stage of preclinical validation. We recently demonstrated that the adoptive transfer of T cell transduced with an HLA-A2-restricted T-cell receptor (TCR), which recognize human TERT with high avidity, controls human B-cell chronic lymphocytic leukaemia (B-CLL) progression without severe side-effects in humanized mice. In the present report, we show the ability of our approach to limit the progression of more aggressive leukemic pathologies, such as acute myeloid leukaemia (AML) and B-cell acute lymphoblastic leukaemia (B-ALL). Together, our findings demonstrate that TERT-based adoptive cell therapy is a concrete platform of T cell-mediated immunotherapy for leukaemia treatment.

Facebook - bit.ly/2xznxjV

Twitter - bit.ly/2xzWvsu

LinkedIn - bit.ly/2xzJ6kc

Pintrest - bit.ly/2xzX8SS

Reddit - bit.ly/2hoxI0N

www.Oncotarget.com

Full Text- https://tinyurl.com/yavmxbxt

The genetic heterogeneity of acute myeloid leukemia (AML) and the variable responses of individual patients to therapy suggest that different AML genotypes may influence the bone marrow (BM) microenvironment in different ways. We performed gene expression profiling of bone marrow mesenchymal stromal cells (BM-MSC) isolated from normal C57BL/6 mice or mice inoculated with syngeneic murine leukemia cells carrying different human AML genotypes, developed in mice with Trp53 wild-type or nullgenetic backgrounds. We identified a set of genes whose expression in BM-MSC was modulated by all four AML genotypes tested. In addition, there were sets of differentially-expressed genes in AML-exposed BM-MSC that were unique to the particular AML genotype or Trp53 status. Our findings support the hypothesis that leukemia cells alter the transcriptome of surrounding BM stromal cells, in both common and genotype-specific ways. These changes are likely to be advantageous to AML cells, affecting disease progression and response to chemotherapy, and suggest opportunities for stroma-targeting therapy, including those based on AML genotype.

Facebook - bit.ly/2xznxjV

Twitter - bit.ly/2xzWvsu

LinkedIn - bit.ly/2xzJ6kc

Pintrest - bit.ly/2xzX8SS

Reddit - bit.ly/2hoxI0N

www.Oncotarget.com

Full text- https://tinyurl.com/yde6fsk7

Significant limitations exist in our ability to predict breast cancer risk at the individual level. Circulating microRNAs (C-miRNAs) have emerged as measurable biomarkers (liquid biopsies) for cancer detection. We evaluated the ability of C-miRNAs to identify women most likely to develop breast cancer by profiling miRNA from serum obtained long before diagnosis. 24 breast cancer cases and controls (matched for risk and age) were identified from women enrolled in the High-Risk Breast Program at the UVM Cancer Center. Isolated RNA from serum was profiled for over 2500 human miRNAs. The miRNA expression data were input into a stepwise linear regression model to discover a multivariable miRNA signature that predicts long-term risk of breast cancer. 25 candidate miRNAs were identified that individually classified cases and controls based on statistical methodologies. A refined 6-miRNA risk-signature was discovered following regression modeling that distinguishes cases and controls (AUC0.896, CI 0.804-0.988) in this cohort. A functional relationship between miRNAs that cluster together when cases are contrasted against controls was suggested and confirmed by pathway analyses. The discovered 6 miRNA risk-signature can discriminate high-risk women who ultimately develop breast cancer from those who remain cancer-free, improving current risk assessment models. Future studies will focus on functional analysis of the miRNAs in this signature and testing in larger cohorts. We propose that the combined signature is highly significant for predicting cancer risk, and worthy of further screening in larger, independent clinical cohorts.

Facebook - bit.ly/2xznxjV

Twitter - bit.ly/2xzWvsu

LinkedIn - bit.ly/2xzJ6kc

Pintrest - bit.ly/2xzX8SS

Reddit - bit.ly/2hoxI0N

Full text - http://bit.ly/2mGYI1J

Oncotarget | Interview with Dr. Marene Landstrom & Dr. Reshma Sundar with the Department of Medical Biosciences, Umeå University Sweden talking about their experience publishing "Pro-invasive properties of Snail1 are regulated by sumoylation in response to TGFβ stimulation in prostate cancer"

Facebook - http://bit.ly/2xznxjV

Twitter - http://bit.ly/2xzWvsu

LinkedIn - http://bit.ly/2xzJ6kc

Pintrest - http://bit.ly/2xzX8SS

Reddit - http://bit.ly/2hoxI0N

www.Oncotarget.com

Full text - http://bit.ly/2mlYU6k

"ERβ inhibits cyclin dependent kinases 1 and 7 in triple negative breast cancer"

Abstract - Triple negative breast cancer (TNBC), which comprises approximately 15% of all primary breast cancer diagnoses, lacks estrogen receptor alpha, progesterone receptor and human epidermal growth factor receptor 2 expression. However, we, and others, have demonstrated that approximately 30% of TNBCs express estrogen receptor beta (ERβ), a nuclear hormone receptor and potential drug target. Treatment of ERβ expressing MDA-MB-231 cells with estrogen or the ERβ selective agonist, LY500307, was shown to result in suppression of cell proliferation. This inhibitory effect was due to blockade of cell cycle progression. In vivo, estrogen treatment significantly repressed the growth of ERβ expressing MDA-MB-231 cell line xenografts. Gene expression studies and ingenuity pathway analysis identified a network of ERβ down-regulated genes involved in cell cycle progression including CDK1, cyclin B and cyclin H. siRNA mediated knockdown or drug inhibition of CDK1 and CDK7 in TNBC cells resulted in substantial decreases in proliferation regardless of ERβ expression. These data suggest that the tumor suppressive effects of ERβ in TNBC result from inhibition of cell cycle progression, effects that are in part mediated by suppression of CDK1/7. Furthermore, these data indicate that blockade of CDK1/7 activity in TNBC may be of therapeutic benefit, an area of study that has yet to be explored.

Facebook - http://bit.ly/2xznxjV

Twitter - http://bit.ly/2xzWvsu

LinkedIn - http://bit.ly/2xzJ6kc

Pintrest - http://bit.ly/2xzX8SS

Reddit - http://bit.ly/2hoxI0N

www.Oncotarget.com

Full text - bit.ly/2mlYU6k

Interview with Dr. John R. Hawse from the Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN, USA talking about their paper "ERβ inhibits cyclin dependent kinases 1 and 7 in triple negative breast cancer"

Facebook - http://bit.ly/2xznxjV

Twitter - http://bit.ly/2xzWvsu

LinkedIn - http://bit.ly/2xzJ6kc

Pintrest - http://bit.ly/2xzX8SS

Reddit - http://bit.ly/2hoxI0N

www.Oncotarget.com

Title - Screening of cancer tissue arrays identifies CXCR4 on adrenocortical carcinoma: correlates with expression and quantification on metastases using 64Cu-plerixafor PET

Abstract - Expression of the chemokine receptor CXCR4 by many cancers correlates with aggressive clinical behavior. As part of the initial studies in a project whose goal was to quantify CXCR4 expression on cancers non-invasively, we examined CXCR4 expression in cancer samples by immunohistochemistry using a validated anti-CXCR4 antibody. Among solid tumors, we found expression of CXCR4 on significant percentages of major types of kidney, lung, and pancreatic adenocarcinomas, and, notably, on metastases of clear cell renal cell carcinoma and squamous cell carcinoma of the lung. We found particularly high expression of CXCR4 on adrenocortical cancer (ACC) metastases. Microarrays of ACC metastases revealed correlations between expression of CXCR4 and other chemokine system genes, particularly CXCR7/ACKR3, which encodes an atypical chemokine receptor that shares a ligand, CXCL12, with CXCR4. A first-in-human study using 64Cu-plerixafor for PET in an ACC patient prior to resection of metastases showed heterogeneity among metastatic nodules and good correlations among PET SUVs, CXCR4 staining, and CXCR4 mRNA. Additionally, we were able to show that CXCR4 expression correlated with the rates of growth of the pulmonary lesions in this patient. Further studies are needed to understand better the role of CXCR4 in ACC and whether targeting it may be beneficial. In this regard, non-invasive methods for assessing CXCR4 expression, such as PET using 64Cu-plerixafor, should be important investigative tools.

Full text - http://bit.ly/2hwPKOq

Facebook - bit.ly/2xznxjV

Twitter - bit.ly/2xzWvsu

LinkedIn - bit.ly/2xzJ6kc

Pintrest - bit.ly/2xzX8SS

Reddit - bit.ly/2hoxI0N

www.Oncotarget.com

The Featured Cover Paper for the most recent issue of @Oncotarget -http://bit.ly/2yG5wlh

A Priority Research Paper by Pongas, et al. titled “PI3Kδ inhibition causes feedback activation of PI3Kα in the ABC subtype of diffuse large B-cell lymphoma”

The corresponding author is Dr. Louis M. Staudt from the Lymphoid Malignancies Branch of the National Cancer Institute at National Institutes of Health in Bethesda, MD, USA.

Please share your thoughts or ask questions about the research on our Facebook page.